BCMA靶向CAR-T治疗难治性SLE与SSc的1期试验
该进行中的1期试验评估了BCMA靶向CAR-T疗法HBI0101在6例重度难治性系统性红斑狼疮(n=3)或系统性硬化症(n=3)患者中的安全性与初步疗效。中位随访6个月,观察到可接受的安全性特征及早期临床活性,支持进一步前瞻性评估。
要点
- 3-4级中性粒细胞减少见于2例,经支持治疗管理。
- 细胞因子释放综合征见于5例(2级3例、1级2例),无ICANS。
- SLE中2例SLEDAI-2K降至0、1例降至4;SSc中3例皮肤受累均改善。
核心结论
- HBI0101在重度难治性SLE或SSc患者中显示可接受的安全性特征和早期临床活性。
研究设计与样本
- 进行中的1期试验,纳入6例重度SLE(n=3)或SSc(n=3)患者,中位年龄41岁(范围21-65),中位病程2.7年(范围1.1-20.5),既往中位3.5线免疫调节治疗(范围2-9),中位随访6个月(范围6-9)。
主要发现
- 3-4级中性粒细胞减少发生于2例,经支持治疗管理;3例出现低丙种球蛋白血症需静脉注射免疫球蛋白替代。
- 细胞因子释放综合征发生于5例(2级3例、1级2例),1例未发生;未观察到免疫效应细胞相关神经毒性综合征。
- SLE中2例SLEDAI-2K降至0、1例降至4;SSc中3例皮肤受累均改善,改良Rodnan皮肤评分和EUSTAR活动指数下降。
关键数值与推荐
- SLE疗效以SLEDAI-2K评估:2例降至0,1例降至4。
- SSc疗效以改良Rodnan皮肤评分和EUSTAR活动指数评估:3例均显示下降。
临床怎么用
- 对于重度难治性SLE或SSc,BCMA靶向CAR-T可作为探索性治疗选择,需在临床试验框架内评估。
- 治疗期间需监测中性粒细胞减少、低丙种球蛋白血症和细胞因子释放综合征,并给予相应支持治疗。
局限性
- 样本量小(共6例),随访时间短(中位6个月),为进行中的1期试验,疗效需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and preliminary efficacy of HBI0101, B cell maturation antigen targeted chimeric antigen receptor T cell therapy, in patients with severe refractory systemic lupus erythematosus or systemic sclerosis. METHODS: We conducted an ongoing phase 1 trial of HBI0101 in six patients with severe systemic lupus erythematosus (n = 3) or systemic sclerosis (n = 3). The median age was 41 years (range: 21-65), the median disease duration was 2.7 years (range: 1.1-20.5), and patients had received a median of 3.5 previous lines of immunomodulatory therapy (range: 2-9). The median follow-up was six months (range: 6-9). RESULTS: Grade 3 to 4 neutropenia occurred in two patients and was managed with supportive care. Three patients had hypogammaglobulinemia requiring intravenous immunoglobulin replacement. Cytokine release syndrome occurred in five patients (grade 2 in three and grade 1 in two) and was absent in one patient. No immune effector cell-associated neurotoxicity syndrome was observed. In systemic lupus erythematosus, the Systemic Lupus Erythematosus Disease Activity Index 2000 decreased to 0 in two patients and to 4 in one patient. In systemic sclerosis, skin involvement improved in all three patients with reductions in modified Rodnan skin score and European Scleroderma Trials and Research activity indices. CONCLUSION: HBI0101 demonstrated an acceptable safety profile and early clinical activity in patients with severe refractory systemic lupus erythematosus or systemic sclerosis, supporting further prospective evaluation.
引用
- Kfir-Erenfeld S, Elias S, Asherie N, et al. B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42098533. doi:10.1002/art.70211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。